Autonomix Medical, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Bradley A. Hauser
- Full Time Employees
- 10
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 21 Waterway Avenue The Woodlands TX United States of America 77380
- IPO Date
- Jan 29, 2024
- CIK
- 0001617867
- Website
- autonomix.com
- Similar Companies
- Business
- Autonomix Medical, Inc. is a medical device company specializing in the development and commercialization of precision nerve-targeted therapies to transform the treatment of peripheral nervous system diseases. The company’s core products include a proprietary platform that utilizes precision guidance technology combining nerve sensing and radio frequency (RF) ablation to sense, treat, and verify nerve signaling through a minimally invasive, transvascular procedure. This platform initially targets severe pain associated with pancreatic cancer and aims to provide rapid, effective, and durable pain relief while enabling significant opioid reduction in patients. Autonomix leverages this first-in-class platform technology across multiple potential therapeutic areas including chronic pain management, hypertension, cardiology, pulmonology, and gastroenterology. The company’s technology is protected by an extensive intellectual property portfolio encompassing over 120 issued or pending patents globally. Founded in 2009 and headquartered in The Woodlands, Texas, Autonomix operates primarily in the United States while advancing global clinical development. Recent major developments include successful progression through a first-in-human proof-of-concept clinical study that demonstrated sustained, clinically meaningful improvements in quality of life and pain reduction for pancreatic cancer patients. This study underpins the company’s planned multicenter pivotal clinical trial in the U.S. set to begin in 2026, supporting its regulatory pathway toward a De Novo FDA classification expected by 2027. Autonomix also commenced a Good Laboratory Practice (GLP) preclinical study for its combined sensing and ablation system and has raised over $15 million through private placements and public offerings during 2024 and 2025 to fund ongoing clinical and regulatory activities. The company is expanding its pipeline beyond pancreatic cancer, exploring applications in cardiovascular, pulmonary, and chronic pain indications. Autonomix maintains active clinical site agreements and strategic partnerships to support its clinical trial execution and is highlighted frequently in scientific conferences to showcase its innovative technology and clinical progress.
Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform
Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
Autonomix Medical wins new patent for neural sensing technology
Autonomix Medical wins new patent for neural sensing technology
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
Autonomix Medical Announces Standalone Neural Sensing Program with Evidence of Real-Time Renal Nerve Activity Change
Autonomix Announces Reverse Stock Split
Autonomix Announces Reverse Stock Split
Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Global Scientific and Clinical Recognition of Platform Technology
Autonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicine
Autonomix Medical Highlights Clinical Data Presented at Society of Surgical Oncology Annual Meeting in Virtual Investor "What This Means" Segment Featuring City of Hope Chief of Medicine
Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation
Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation
Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
Autonomix Medical Announces Abstract Acceptances at EuroPCR 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
Autonomix Medical Announces Abstract Acceptance at Digestive Disease Week 2026 Showcasing Long-Term Data in Pancreatic Cancer Pain Mitigation
Critical Review: Autonomix Medical (NASDAQ:AMIX) and Pacific Biosciences of California (NASDAQ:PACB)
Autonomix Medical to Present Long-Term Pain Mitigation Data in Pancreatic Cancer at ECIO 2026